

Long Term Inhibition of Hepatitis B Virus reactivation by Antiviral therapy in immunosuppressed Patients

Thesis

Submitted to Biochemistry Department

Faculty of Science
Ain Shams University

By

Amr Mohammed Shaaban

(M.Sc Biochemistry)

Supervised By

Prof. Dr Amr Mahmoud Karim
Professor of Biochemistry
Faculty of Science
Ain Shams University

Prof.Dr Manal Hamdy ElSayed
Professor of Pediatrics
Faculty of Medicine
Ain Shams University

Dr.Gamila Mohamed Labib Shanab
Assistant .Professor of Biochemistry
Faculty of Science, Ain Shams University

(2013)

CONTENTS

Abstract	X
List of Abbreviations	VIII
List of Figures	VII
List of Tables	V
Aim of the Work	XI
1. INTRODUCTION	
1.1. Viral Hepatitis	1
1.2. Hepatitis B Virus (HBV)	2
1.2.1 Disease	4
1.2.2 Epidemiology	5
1.2.3 Chronic HBV infection	7
1.3 HBV Serological Markers	8
1.3.1. HBsAg (Hepatitis B Surface Antigen)	8
1.3.2. HBeAg (Hepatitis B Envelope Antigen)	8
1.3.3. HBcAg (Hepatitis B core Antigen)	9
1.3.4. Anti-HBs and Anti-HBe Antibodies	10
1.3.5. PCR Detection of hepatitis B Virus	12
1.4. Historical background of vaccination and vaccine	

Strategy	13
1.5. Genomic organization of HBV	15
1.5.1 Viral gene and protein	15
1.5.2. HBV Genotypes & Subgenotypes	18
1.6 Viral Replication Cycle	24
1.7 Hepatitis B Treatments	26
1.7.1 Interferon	29
1.7.2 Antiviral Drugs	30
1.7.2a Lamivudine	30
1.7.2aI Mechanism of Action	32
1.7.2aII HBV Drug Resistance	32
1.7.2aIII Drug Interaction	33
1.7.2b Other Nucleotide Analogues	33
1.7.2bI Adefovir	33
1.7.2bII Tenofovir	34
1.7.2bIII Entecavir	34
1.7.2bIV Deoxythymidine	34
1.8. Therapeutic Response	34
1.9. Combination Therapy	36
1.10. Influence of HBV genotype on the response to	
Antiviral therapy	36
1.11 Treatment of patients with HBeAg –positive	
Chronic hepatitis B	37

1.12 Treatment of patients with HBeAg-negative	
Chronic hepatitis B	37
1.13 Long-term therapies in native patients	38
 2. MATERIAL AND METHODS	
2.1. Materials	40
2.1.1. Serum	40
2.1.2. Chemicals	41
2.1.3. Enzymes	41
2.1.4. Kits	41
2.1.5 Supplies	41
2.1.6 Reagents and Solutions	41
2.2-Methods	46
2.2.1. Determination of Hepatitis B Surface Antigen	43
2.2.2. Determination of Hepatitis B e Antigen	47
2.2.3. Determination of total Hepatitis B Core Antibody	48
2.2.4. Determination of total Hepatitis B e Antibody	50
2.2.5. Determination of Antibodies to Hepatitis B Surface Antibody (anti-HBs)	52
2.2.6. Detection of HBV viral DNA by Qualitative PCR	54
2.2.7. Quantitative determination of HBV viral load By REAL-TIME PCR	56
2.2.7a. Simultaneous isolation of total nucleic acids	

(DNA/RNA) from serum	56
2.2.7b. Dye Selective Chart	58
2.2.8. Determination of CK NAC UV	61
2.2.9. Determination of Pancreatic Amylase Liquid	62
2.3. Statistical Analysis	
 3. RESULTS	 63
4. DISCUSSION	76
5. CONCLUSION	91
6. SUMMARY	94
REFERENCES	97
ARABIC SUMMARY	
ARABIC ABSTRACT	

LIST OF TABLES

Table No.	Title	Page
Introduction		
1	Human Hepatitis Viruses A-E and G.	1
2	The Type of HBV.	4
3	Molecular components of HBV	16
4	Orthohepadnaviruses and their host	18
5	Fundamental properties of genomes and differences between HBV genotype	20
6	Direct relationship between the main antigenic subtypes of HBV and amino acid identity (Lys or Arg) at two positions (120 and 160) in the S protein.	21
7	HBV subgenotypes and geographic prevalence.	23
8	Efficacy of currently available agents in the treatment of chronic hepatitis B	27
9	Comparison of IFN, Peg interferon alfa-2a, Lamivudine, Entecavir, and Adefovir Dipivoxil in HBeAg-Positive CHB	28
10	Definitions of response to therapy in chronic hepatitis B.	35
11	Nomenclature, Prevention, and Potential Management of Antiviral Resistance.	39
MATERIAL AND METHODS		

1	Initial concentration of the HBV DNA	60
RESULTS		
1	Pateints statistics	64
2	Duration of malignancy diagnosis and first visit dates for studies pateints	65
3	Age, duration of, follow-up and biochemical tests result	66
4	Frequency of positive and negative serological HBV markers and HBV (PCR) at different times of the study	67
5	HBsAg status at final time	70
6	HBsAb status at final time compared to zero time.	71
7	HBeAg status at final time compared to zero time	72
8	HBeAb status at final time compared to zero time	73
9	Seroconversiton of HBeAg to HBeAb Crosstabulation	74
Discussion		
1	Trials of prophylactic lamivudine in lymphoma pateints for the prevention of hepatitis B reactivation	80

LIST OF FIGURES

Fig. No.	Title	Page
1	The diagram of structure of HBV	4
2	Transcriptional and translational map of HBV	16
3	The infectious virion genome.	17
4	Phylogenetic tree showing relationships between representative HBV strains derived from primates.	19
5	Geographic distribution of HBV genotypes and subgenotypes.	22
6	The Replication Cycle of HBV.	24
7	Putative life cycle of HBV.	25
8	Mutation in HBV that confer resistance to antiviral drugs.	38
RESULT		
1	Gender distribution among studies patients	64
2	Distribution of different types of malignancies	65
3	HBsAg status at final time compared to HBsAg and HBsAb status at zero time	70
4	HBeAg status at final time as compared to HBeAg at zero time	72
5	HBeAb status at final time as compared to HBeAg and HBeAb at zero time	73

List of Abbreviations

ALP: Alkaline phosphatase.

ALT: Alanine amino transferase.

Anti- HAV: Antibody to hepatitis A virus.

Anti- HBV: Antibody to hepatitis B virus.

Anti- HCV: Antibody to hepatitis C virus.

Anti- HDV: Antibody to hepatitis D virus.

Anti- HEV: Antibody to hepatitis E virus.

Anti-HBc: Antibody to hepatitis B core antigen.

Anti-HBe: Antibody to hepatitis B envelope antigen.

Anti-HBs: Antibody to hepatitis B surface antigen.

AST: Aspartate aminotransferase.

bp: Base Pair.

CAH: Chronic Active Hepatitis.

CccDNA: Covalently closed circular DNA.

CHB: Chronic Hepatitis B.

ELISA: Enzyme linkage immuno sorbent assay.

GGT: Gamma glutamyl transferase.

HAV: Hepatitis A Virus.

HAV-Ag: Hepatitis A virus antigen.

HBeAg: Hepatitis B envelop antigen.

HBV: Hepatitis B virus.

HCC: Hepato Cellular Carcinoma.

HCV: Hepatitis C virus.

HDV: Hepatitis D virus.

HEV: Hepatitis E virus.

HFV: Hepatitis F virus.

HGV: Hepatitis G virus.

HIV: Human immunodeficiency virus.

IHAB: Immune Heam Agglutination for bilharzias.

HBsAg: HEPATITIS B SURFACE ANTIGEN.

HBeAb: TOTAL ANTIBODIES TO HEPATITIS E ANTIGEN.

HBsAb: HEPATITIS B SURFACE ANTIBODIES.

PCR: POLY CHAIN REACTION.

CK: CREATININKINASE CATALYZES

BMT: Bone Marrow Transplantation

NSAID: Non-Steroidal-anti-inflammatory

ABSTRACT

In Order to evaluate the long term effect of antiviral lamivudine therapy on HBV reactivation in pateints with malignancies and receiving immunocompromising therapies, thirty seven HBsAg positive children and adolescents undergoing immunosuppressive, treatment were treated with lamivudine 3 mg/kg body weight (Up to 100 mg) daily over a period of up to 87 months during which biochemical, serological and virological response was followed periodically. The result demonstrated a significant decrease in the mean AST (216.2 IU/L to 82.7 IU/L) and ALT (233.2 IU/L to 91.3 IU/L) within the first 6 months of treatment with lamivudine. At the end of the study period, HBsAg positivity decreased to 70.3. HBsAb increased to 16.2% by the end of the study compared to 5.4% at baseline. HBeAg decreased from 70.3% at baseline to 29.7% at the end of the study. HBeAb increased from 10.8% at baseline to 35.1% at the end of study. HBcAg & HBV-DNA incidence at base line was 86.5% and 75.7% respectively .All pateints became HBV-DNA negative during the study; however seven pateints became HBV-DNA again indicating resistance to lamivudine.

AIM OF WORK

Administration of immunosuppressive treatment in hepatitis B virus carriers with malignancies is associated with risk hepatitis B reactivation.

The aim of the work is evaluation of long term effect of antiviral therapy (Lamivudine) on chemotherapy – induced HBV reactivation.

ACKNOWLEDGEMENT

“ FIRST OF ALL, THANKS FOR GOD “

I would like to seize this opportunity to offer my deep gratitude and appreciation to **Prof. Dr. Amr Mahmoud Karim**, Professor of Biochemistry, Faculty of Science, Ain Shams University, for his uncountable help, master teaching, instructive guidance, sincere help, and valuable support throughout the course of this study. It's a great honor to work under his supervision and I am really very proud to be his student.

My deep thanks to **Dr. Manal Hamdy El-Sayed**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her honest supervision, big efforts and continuous encouragement during the progress of this work.

My deep thanks to **Dr. Gamila Mohamed Labib Shanab**, Assistant Professor of Biochemistry, Faculty of Science, Ain Shams University, for her honest supervision, big efforts and continuous encouragement during the progress of this work.

I wish to thank *Prof.Dr. Mohamed Ragaey Mohamed & Dr/ Nahla El-Ghazali* for his cooperation and his helpful aid and his progressive support.

Special thanks for the patients who accept to cooperate with us in order to conduct this work.

Last but not least, my thanks and best regards to the staff members of Molecular Biology Service Unit , Biochemistry Department Faculty of Science, Ain Shams University, to my professors and colleagues, for their cooperation and giving me the chance to learn in the department.

Thanks

Amr Mohammed Shaaban

بسم الله الرحمن الرحيم

" قالوا سبحانك لا علم لنا الا ما علمتنا انك أنت
العليم الحكيم "

صدق الله العظيم

سورة البقرة، الآية 32

1-Introduction

1.1.Viral Hepatitis

Many viruses can affect liver function and morphology indirectly, such as Epstein-Barr virus, cytomegalovirus, rubella, adenoviruses, yellow fever virus... (**WHO, 1973**). However, “viral hepatitis” is a general term that is reserved for infection of the liver caused by one of at least eight human viral agents that have been discovered and characterized (Table 1) (**Levine *et al.*, 1999; Dusheika, 1990; Hollinger, 1996**). These viruses are named A through G, and possess distinctive immunoserologic characteristics.

Table 1: Human Hepatitis Viruse A-E and G (Levine *et al.*, 1999)

Name of Virus (Abbreviation)	Viral Genome	Mode of Transmission	Diagnostic Tests
Heapatiotis A (HAV)	7.5 kb single strand RNA	Enteric (fecal/oral)	ALT, antibodies to HAV
Hepatitis B (HBV)	3.2 double stranded DNA	Parenteral or percutaneous	ALT, HBV antiges, antibodies to HBV, HBV DNA
Hepatitis C (HCV)	9.5 kb single stranded RNA	Parenteral or percutaneous	ALT, antibodies to HCV, HCV RNA
Hepatitis D	1.7 kb single-	Parenteral or percutaneous	Antibodies to HDV, HDAg,